相关实验视频
Updated: Jan 8, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.3K
手术后服用口服止痛药后的低血糖症:一个案例系列
Tashfeen Ahmad1, Zehra Abdul Muhammad1
1Department of Surgery, Aga Khan University, Karachi, Pakistan.
JPMA. The Journal of the Pakistan Medical Association
|December 19, 2025
概括
某些止痛药可能会增加糖尿病和高血压的老年骨折患者的低血糖风险. 同时服用抗糖尿病和抗高血压药物可能会增加这种风险.
科学领域:
- 药理学 药理学是指药理学的学科.
- 老年医学 老年医学
- 整形外科手术 整形外科手术
背景情况:
- 止痛药相关的低血糖是罕见但显著的不良事件.
- 患有糖尿病和高血压等并发症的老年患者尤其容易受到伤害.
研究的目的:
- 在骨折患者接受手术后口服止痛药时,调查低血糖的发生情况.
- 确定导致这种不良事件的潜在风险因素和药物相互作用.
主要方法:
- 对288名成年骨折患者的前性队列研究 (靠近大腿骨,脚,后脚).
- 在出院后两周内监测处方止痛药和不良事件.
- 对患有低血糖症的病例进行分析,重点关注同时服用的药物.
主要成果:
- 在糖尿病和高血压的老年患者中观察到5例低血糖症.
- 在与抗糖尿病和抗高血压药物一起服用止痛药后出现低血糖症.
- 处方的止痛药包括乙氨基,特拉马多尔-乙氨基,普雷加巴林,塞莱科克西布,埃托里科克西布,迪克洛芬尼克-米索普罗斯托尔,塔多尔和凯托洛拉克甲胺.
结论:
- 某些止痛药可能会增强老年糖尿病和高血压骨折患者的低血糖风险.
- 建议在止痛药和其他药物 (抗高血压药,抗糖尿病药) 之间有潜在的组合作用.
- 需要进一步研究危险人群中止痛药相关的低血糖症.
关键词:
低血糖; 止痛药; 骨折.相关概念视频
Hypoglycemia and Glucagon
772
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
772
Oral Hypoglycemic Agents: Glinides
565
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
565
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
505
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
505
Oral Hypoglycemic Agents: Biguanides and Glitazones
562
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
562
SBAR II: Application of SBAR
5.6K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
5.6K
Oral Hypoglycemic Agents: Sulfonylureas
724
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
724

